Literature DB >> 28893733

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Christopher D Carey1,2, Daniel Gusenleitner3, Mikel Lipschitz3, Margaretha G M Roemer4,5, Edward C Stack6, Evisa Gjini3, Xihao Hu7, Robert Redd7, Gordon J Freeman3,4, Donna Neuberg7, F Stephen Hodi3,4, Xiaole Shirley Liu7, Margaret A Shipp3,4, Scott J Rodig1,3.   

Abstract

Signaling between programmed cell death protein 1 (PD-1) and the PD-1 ligands (PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg (HRS) cells to evade antitumor immunity in classical Hodgkin lymphoma (cHL). Copy number alterations of 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) contribute to robust PD-L1 and PD-L2 expression by HRS cells. PD-L1 is also expressed by nonmalignant tumor-associated macrophages (TAMs), but the relationships among PD-L1+ HRS cells, PD-L1+ TAMs, and PD-1+ T cells remain undefined. We used multiplex immunofluorescence and digital image analysis to examine the topography of PD-L1+ and PD-1+ cells in the tumor microenvironment (TME) of cHL. We find that the majority of PD-L1 in the TME is expressed by the abundant PD-L1+ TAMs, which physically colocalize with PD-L1+ HRS cells in a microenvironmental niche. PD-L1+ TAMs are enriched for contacts with T cells, and PD-L1+ HRS cells are enriched for contacts with CD4+ T cells, a subset of which are PD-1+ Our data define a unique topology of cHL in which PD-L1+ TAMs surround HRS cells and implicate CD4+ T cells as a target of PD-1 blockade.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28893733      PMCID: PMC5766840          DOI: 10.1182/blood-2017-03-770719

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

2.  Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Robert A Redd; Geraldine S Pinkus; Yasodha Natkunam; Azra H Ligon; Courtney F Connelly; Christine J Pak; Christopher D Carey; Sarah E Daadi; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Margaret A Shipp; Scott J Rodig
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

Review 4.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

Review 5.  Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Authors:  Linh T Nguyen; Pamela S Ohashi
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

6.  Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma.

Authors:  A Diepstra; M Niens; E Vellenga; G W van Imhoff; I M Nolte; M Schaapveld; G van der Steege; A van den Berg; R E Kibbelaar; G J te Meerman; S Poppema
Journal:  Lancet       Date:  2005 Jun 25-Jul 1       Impact factor: 79.321

7.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

Review 8.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 9.  How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Authors:  Ole Audun Werner Haabeth; Anders Aune Tveita; Marte Fauskanger; Fredrik Schjesvold; Kristina Berg Lorvik; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Zlatko Dembic; Alexandre Corthay; Bjarne Bogen
Journal:  Front Immunol       Date:  2014-04-15       Impact factor: 7.561

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316

View more
  99 in total

1.  Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.

Authors:  Paul J Bröckelmann; Helen Goergen; Ulrich Keller; Julia Meissner; Rainer Ordemann; Teresa V Halbsguth; Stephanie Sasse; Martin Sökler; Andrea Kerkhoff; Stephan Mathas; Andreas Hüttmann; Matthias Bormann; Andreas Zimmermann; Jasmin Mettler; Michael Fuchs; Bastian von Tresckow; Christian Baues; Andreas Rosenwald; Wolfram Klapper; Carsten Kobe; Peter Borchmann; Andreas Engert
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

Review 2.  Where does PD-1 blockade fit in HL therapy?

Authors:  Alex F Herrera
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

4.  Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

Authors:  Fathima Zumla Cader; Ron C J Schackmann; Xihao Hu; Kirsty Wienand; Robert Redd; Bjoern Chapuy; Jing Ouyang; Nicole Paul; Evisa Gjini; Mikel Lipschitz; Philippe Armand; David Wu; Jonathan R Fromm; Donna Neuberg; X Shirley Liu; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2018-06-07       Impact factor: 22.113

5.  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Authors:  Jean-Christophe Pignon; Opeyemi Jegede; Sachet A Shukla; David A Braun; Christine E Horak; Megan Wind-Rotolo; Yuko Ishii; Paul J Catalano; Jonian Grosha; Abdallah Flaifel; Jesse S Novak; Kathleen M Mahoney; Gordon J Freeman; Arlene H Sharpe; F Stephen Hodi; Robert J Motzer; Toni K Choueiri; Catherine J Wu; Michael B Atkins; David F McDermott; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

6.  The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.

Authors:  Sanjay S Patel; Jason L Weirather; Mikel Lipschitz; Ana Lako; Pei-Hsuan Chen; Gabriel K Griffin; Philippe Armand; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2019-12-05       Impact factor: 22.113

Review 7.  Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

Authors:  W Robert Liu; Margaret A Shipp
Journal:  Blood       Date:  2017-11-23       Impact factor: 22.113

8.  Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Authors:  Margaretha G M Roemer; Robert A Redd; Fathima Zumla Cader; Christine J Pak; Sara Abdelrahman; Jing Ouyang; Stephanie Sasse; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Stephen Ansell; Kazunobu Kato; Benedetto Farsaci; Anne Sumbul; Philippe Armand; Donna S Neuberg; Geraldine S Pinkus; Azra H Ligon; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2018-02-02       Impact factor: 44.544

9.  Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Authors:  Stephanie Sasse; Katharina Reddemann; Arjan Diepstra; Ilske Oschlies; Antje Schnitter; Sven Borchmann; Andreas Engert; Peter Borchmann; Wolfram Klapper
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

10.  Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Authors:  Romain Guièze; Vivian M Liu; Daniel Rosebrock; Alexis A Jourdain; María Hernández-Sánchez; Aina Martinez Zurita; Jing Sun; Elisa Ten Hacken; Kaitlyn Baranowski; Philip A Thompson; Jin-Mi Heo; Zachary Cartun; Ozan Aygün; J Bryan Iorgulescu; Wandi Zhang; Giulia Notarangelo; Dimitri Livitz; Shuqiang Li; Matthew S Davids; Anat Biran; Stacey M Fernandes; Jennifer R Brown; Ana Lako; Zoe B Ciantra; Matthew A Lawlor; Derin B Keskin; Namrata D Udeshi; William G Wierda; Kenneth J Livak; Anthony G Letai; Donna Neuberg; J Wade Harper; Steven A Carr; Federica Piccioni; Christopher J Ott; Ignaty Leshchiner; Cory M Johannessen; John Doench; Vamsi K Mootha; Gad Getz; Catherine J Wu
Journal:  Cancer Cell       Date:  2019-09-19       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.